Renaissance Capital logo

Evelo Biosciences Priced, Nasdaq: EVLO

Early-stage biotech developing microbial gut therapies for inflammatory diseases.

Industry: Health Care

First Day Return: +1.6%

Industry: Health Care

Evelo Biosciences is discovering and developing potential therapies designed to act on the gut-body network. The action of our therapies is based on our growing understanding of the central role of the gut in controlling immune and biological activity throughout the body. The gut-body network represents the connections of the gut to all organs and tissues, which enables the gut to exert a significant level of control over the body’s immune and biological systems. The centrality of the gut-body network to the immune system has only recently become appreciated, and modern medicine and drug discovery have largely overlooked the importance of the gut-body network in fighting disease. We believe that we have the potential to use the unexplored biology of the gut-body network to develop novel therapies that could transform the treatment of many major diseases, potentially driving profound benefits to patients and society.
more less

Evelo Biosciences (EVLO) Performance